Skip to main content

Table 2 Clinical characteristics

From: Association between methadone dose and concomitant cocaine use in methadone maintenance treatment: a register-based study

Variables Low dose group (LDG) (n = 200) Medium dose group (MDG) (n = 273) High dose group (HDG) (n = 140) Total sample (N = 613) p value
Specialized centers, n (%)a 114 (57.0) 189 (69.2) 104 (74.3) 407 (66.4) p < 0.01
Methadone dose mg/ day, mean (SD)b 35.0 (±12.1) 81.3 (±14.8) 150.0 (±33.3) 81.9 (±46.6) p < 0.001
Prescribed comedication, n (%)c 77 (38.7) 164 (60.1) 108 (77.1) 349 (57.0) p < 0.001
Allowed take-home days per week, mean (SD)d 5.8 (±3.7) 5.1 (±3.2) 4.5 (±2.7) 5.2 (±3.3) p < 0.001
Length of stay in MMT, mean (SD), ye 9.3 (±4.5) 10.2 (±4.7) 11.3 (±4.8) 10.2 (±4.7) p < 0.001
No. of consultations within 6 months, mean (SD)f 5.9 (±4.2) 6.2 (±4.2) 7.7 (±6.7) 6.4 (±4.9) p < 0.01
Alcohol use in the past 30 days, mean (SD)g 7.4 (±11.1) 8.9 (±11.1) 11.8 (±13.3) 9.1 (±12.1) p < 0.01
Cannabis use in the past 30 days, mean (SD)h 8.5 (±12.1) 8.9 (±12.0) 11.8 (±13.3) 8.3 (±11.2) p > 0.05
  1. Significance level p < 0.05.
  2. aSignificant difference between patients in the LDG, MDG and HDG (Kruskal-Wallis test; χ2 = 12.782; df = 2; p < 0.01). The Mann Whitney test revealed that patients in the LDG were significantly more often treated in office-based settings than patients in the MDG (Z = −2.736; p < 0.01) or in the HDG (Z = −3.266; p < 0.001).
  3. bSignificant difference between patients in the LDG, MDG and HDG for prescribed methadone dose (ANOVA; F(2,610) = 1343.158; p < 0.001).
  4. cSignificant difference between patients in the LDG, MDG and HDG (Kruskal-Wallis test; χ2 = 51.360; df = 2; p < 0.001). The Mann Whitney test revealed that patients in the LDG had a significantly lower proportion of prescribed comedication than patients in the MDG (Z = −4.584; p < 0.001) or in the HDG (Z = −6.990; p < 0.001).
  5. dSignificant differences between patients in the LDG, MDG and HDG for allowed take-home methadone days per week (ANOVA; F(2,603) = 6.750; p < 0.001). Post-hoc tests (Duncan Scheffé’s) revealed that patients in the HDG had significantly fewer take-home days than patients in the LDG (p < 0.001) but not in the MDG (p > 0.05).
  6. eSignificant differences between patients in the LDG, MDG and HDG for length of stay in MMT (ANOVA; F(2,611) = 7.734; p < 0.001). Post-hoc tests (Duncan Scheffé’s) revealed that patients in the HDG had a significantly longer length of stay in MMT than patients in the LDG (p < 0.001) but not in the MDG (p > 0.05).
  7. fSignificant differences between patients in the LDG, MDG and HDG for the number of consultations in the past 6 months (ANOVA; F(2,603) = 5.907; p < 0.01). Post-hoc tests (Duncan Scheffé’s) revealed that patients in the HDG had significantly more consultations than patients in the LDG (p < 0.01) or in the MDG (p < 0.05).
  8. gSignificant differences between patients in the LDG, MDG and HDG for alcohol use in the past 30 days (ANOVA; F(2,598) = 5.087; p < 0.01). Post-hoc tests (Duncan Scheffé’s) revealed that patients in the HDG had significantly more alcohol consumption days than patients in the LDG (p < 0.01) but not in the MDG (p > 0.05).
  9. hNo differences between patients in the LDG, MDG and HDG for cannabis use in the past 30 days (ANOVA; F(2,604) = 0.160; p > 0.05).